Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Relapsed or Refractory Multiple Myeloma
NCT06282978Phase 2Active, not recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Fundación PETHEMA. Started Nov 2023; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06282978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282978.